Technology
Health
Biotechnology

Aravive

$5.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-2.80%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Aravive and other stocks, options, ETFs, and crypto commission-free!

About ARAV

Aravive, Inc. Common Stock, also called Aravive, is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Read More Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Employees
14
Headquarters
Houston, Texas
Founded
2008
Market Cap
60.33M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
24.73K
High Today
$5.55
Low Today
$5.09
Open Price
$5.30
Volume
76.18K
52 Week High
$12.60
52 Week Low
$3.07

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2014 IPO
US
North America

ARAV Earnings

-$0.50
-$0.45
-$0.39
-$0.34
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.